Multiple myeloma trials in China

In China 203 Also abroad 703

203 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma
Where
Tianjin
Age
18 years and over
People
20
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07409454
No phaseTaking people
Longitudinal Data Registry of Plasma Cell Dyscrasia
Where
Shanghai
Age
19 years to 99 years
People
2,000
Run by
Shanghai Zhongshan Hospital
See details and how to joinNCT06760052
Phase 2Taking people
A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).
Where
Shanghai
Age
18 years and over
People
30
Run by
Shanghai Zhongshan Hospital
See details and how to joinNCT07638683
Phase 1Taking people
A Clinical Study of SHR-5421 in Patients With Multiple Myeloma
Where
Beijing
Age
18 years and over
People
97
Run by
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
See details and how to joinNCT07652281
Phase 1Not yet taking people in China
A Study of KIV-318 Injection in Patients With BCMA-Positive Relapsed/Refractory Multiple Myeloma
Where
Tianjin
Age
18 years to 70 years
People
30
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07726160
No phaseTaking people
BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma
Where
Tianjin
Age
18 years to 78 years
People
20
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT06745687
Early phase 1Taking people
A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma.
Where
Wuhan
Age
18 years and over
People
24
Run by
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07429721
Early phase 1Taking people
Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases
Where
Fuzhou
Age
18 years to 80 years
People
50
Run by
First Affiliated Hospital of Fujian Medical University
See details and how to joinNCT04504526
Early phase 1Taking people
An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies
Where
Wuhan
Age
18 years to 75 years
People
40
Run by
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07101705
Phase 1Taking people
In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma
Where
Kunming
Age
18 years and over
People
15
Run by
Chongqing Precision Biotech Co., Ltd
See details and how to joinNCT07715630
Phase 4Not yet taking people in China
A Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly Diagnosed Multiple Myeloma Patients With t(11;14) Suitable for Transplantation Using the SonKRd Regimen
Where
Suzhou
Age
18 years and over
People
20
Run by
The First Affiliated Hospital of Soochow University
See details and how to joinNCT07709884
Phase 3Taking people
A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
Where
Beijing, Guangzhou, Hangzhou, Luoyang, Suzhou, Taiyuan, Tianjin, Wuhan, Xi'an, Zhengzhou
Age
18 years to 75 years
People
360
Run by
Hangzhou Sumgen Biotech Co., Ltd.
See details and how to joinNCT06508983
Phase 1/2Taking people
To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma
Where
Hangzhou, Suzhou, Xi'an, Zhengzhou
Age
18 years to 80 years
People
40
Run by
Hangzhou Sumgen Biotech Co., Ltd.
See details and how to joinNCT07454187
Phase 1/2Not yet taking people in China
Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification
Where
Tianjin
Age
18 years to 70 years
People
50
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07687004
Phase 4Taking people
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
Where
Beijing, Guangzhou, Hangzhou, Jinan
Age
18 years and over
People
80 worldwide
Run by
Pfizer
See details and how to joinNCT06057402 · EU 2023-505200-33-00
No phaseTaking people
Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
Where
Beijing, Chengdu, Guangzhou, Harbin, Kunming, Naning, Nanjing, Nantong, Shanghai, Shenzhen, Wuhan, Xi’an, Zhengzhou
Age
18 years and over
People
333
Run by
Shanghai Zhongshan Hospital
See details and how to joinNCT07663253
Phase 2/3Taking people
68Ga-BCMA PET/CT in Multiple Myeloma
Where
Beijing, Jilin City, Shijiazhuang
Age
18 years to 80 years
People
300
Run by
Peking University First Hospital
See details and how to joinNCT07319897
Phase 1Taking people
Safety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple Myeloma
Where
Suzhou
Age
18 years to 70 years
People
18
Run by
The First Affiliated Hospital of Soochow University
See details and how to joinNCT07652138
Early phase 1Not yet taking people in China
Safety and Efficacy of RN9101 in the Treatment of Relapsed/Refractory Multiple Myeloma
Where
Nanjing
Age
18 years and over
People
19
Run by
The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT07628595
Phase 2Taking people
Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
Where
Tianjin
Age
18 years and over
People
160
Run by
Qilu Pharmaceutical Co., Ltd.
See details and how to joinNCT07018050
Phase 1Taking people
A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
Where
Chengdu
Age
18 years and over
People
33
Run by
Sichuan Baili Pharmaceutical Co., Ltd.
See details and how to joinNCT07255898
Phase 1Taking people
A Phase I Study of SHR-3836 in Patients With Multiple Myeloma
Where
Suzhou
Age
18 years and over
People
99
Run by
Shanghai Hengrui Pharmaceutical Co., Ltd.
See details and how to joinNCT07490613
Phase 3Taking people
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
Where
Tianjin
Age
18 years and over
People
228
Run by
Qilu Pharmaceutical Co., Ltd.
See details and how to joinNCT07138209
Phase 3Taking people
A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma
Where
Tianjing
Age
18 years and over
People
261
Run by
Shandong New Time Pharmaceutical Co., LTD
See details and how to joinNCT07579234
Phase 3Not yet taking people in China
Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
Where
Beijing, Bengbu, Binzhou, Cangzhou, Changsha, Changzhi, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Jining, Kunming, Lanzhou, Luoyang, Luzhou, Nanchang, Nanjing, Nanning, Ningbo, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Ürümqi, Xi'an, Xi’an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou
Age
18 years to 75 years
People
260
Run by
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
See details and how to joinNCT07569757